Blood Stream Infection Testing Market to Observe Significant Growth Due to Technological Advancements and Company Acquisitions by Market Players, such as BD, Bruker Corporation, and Others

The human body is complex and contains various important systems among which one of the most significant one is the circulatory system. The circulatory system uses blood to supply nutrients throughout the body. In certain instances, the blood may get infected with microorganisms such as viruses that may result in severe effects in the body if not detected in the earlier stages. Blood stream infection testing is one such method that directly detects any abnormality present in a human’s blood, allowing for quicker treatment.

COVID-19 Impact on the Industry

The rapid spread of COVID-19 all over the world led to major losses to various industries and organizations. The healthcare sector saw immense surge due to the urgent requirement to detect and find a solution to the virus. The pandemic resulted in a requirement for blood testing at a faster rate and the blood stream infection testing method turned to be one of the sought after for detection of the virus. This led to a massive growth of the blood stream infection testing market during the pandemic and is expected to see a continued rise. 

Key Trends & Developments in Blood stream infection testing market

Several healthcare organizations and laboratories along with corporates are trying to come up with further enhancements in medical care; such advancements are predicted to aid the growth of the blood stream infection testing market. For instance,

• In March 2020, Becton, Dickinson, and Company, a pioneer in medical technology, partnered with BioMedonomics, a highly renowned clinical diagnostic organization, to launch a point-of-care test. The point-of-care test is capable of detecting an individual’s exposure to COVID-19 real time or in the past. The point-of-care test can take up to a minimal 15 minutes for the results, which helps in early detection and doesn’t require any complex equipment.
   
• In September 2020, Biomedical Advanced Research and Development Authority (BARDA), a U.S government organization that assists in funding and research, with the combined efforts of Luminex Corporation, a biotech company and manufacturer of testing equipment,  was able to come up with an extremely competent high throughput test. This test is highly accurate and productive as it is capable of scanning thousands of samples for any sign of viruses and antibodies.
   
• In January 2021, Bruker Corporation a manufacturer of scientific material, received clearance from the US FDA to launch the MBTSepsityper Kit US IVD. The kit is effective in scanning the blood samples for over 425 types of disease-causing elements. It gives rapid results which allow quick analysis and even quicker diagnosis. The test kit is cost effective and can allow physicians to take decisions that can potentially save a patient’s life.

Forecast Analysis of Blood stream infection testing market

The global blood stream infection testing market has been seeing an exponential rise due to the COVID-19 pandemic and is predicted to see further growth during the forecast period. The world today is in dire need of effective and fast virus detection techniques due to the highly fatal nature of the coronavirus.  Blood stream infection analysis has pushed the healthcare and medical industry along with scientific researchers to look for further advancements that in the future can help in preventing occurrences such as a pandemic. This need to explore the field of blood stream infection is also one of the major reasons for the growth of the blood stream infection testing market.

A recently published report by Research Dive has stated that the global blood stream infection testing market is set to garner revenue of $10,540.8 million by 2030. Moreover, North America region is expected to be the leading contributor to the market growth. A large number of key players, such as Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Becton Dickinson, Cepheid, bioMérieux SA, Luminex Corporation, AdvanDX, Accelerate Diagnostics Inc., and Bruker Corp have given their contribution for further advancements and research in the market.